0000000000501264

AUTHOR

L Provinciali

showing 4 related works from this author

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

2011

none 25 no Abstract OBJECTIVES: To evaluate the incidence and dose-dependency of mitoxantrone (MTX)-associated acute myelocytic leukemia (AML) in the network of Italian multiple sclerosis (MS) clinics. METHODS: We performed a multicenter retrospective cohort study of patients treated with MTX in MS centers under the Italian national health care system between 1998 and 2008. Demographic, disease, treatment, and follow-up information were collected using hospital records. RESULTS: Data were available for 3,220 patients (63% women) from 40 Italian centers. Follow-up (mean ± SD) was 49 ± 29 months (range 12-140 months). We observed 30 cases of AML (incidence 0.93% [95% confidence interval 0.60%…

Malemedicine.medical_specialtyMyeloidmitoxantrone; acute myelocytic leukemia; multiple sclerosisPopulationmultiple sclerosisStatistics NonparametricmitoxantroneFollow-Up StudieArts and Humanities (miscellaneous)Retrospective StudieInternal medicineMultiple SclerosimedicineHumansmultiple sclerosis leukemia mitoxantroneProspective cohort studyeducationRetrospective StudiesAgedAnalgesicseducation.field_of_studyMitoxantroneCumulative dosebusiness.industryMultiple sclerosisIncidence (epidemiology)leukemiaMyeloid leukemiaRetrospective cohort studymedicine.diseaseConfidence intervalSurgeryLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureItalyCohortSettore MED/26 - NeurologiaAnalgesicFemaleNeurology (clinical)acute myelocytic leukemiaMitoxantronebusinessFollow-Up Studiesmedicine.drugHuman
researchProduct

Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of th…

2013

ObjectiveTo assess the effects of subcutaneous (sc) interferon (IFN) -1a on cognition over 5 years in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS).MethodsPatients aged 18-50 years with RRMS (Expanded Disability Status Scale score ≤4.0) who had completed the 3-year COGIMUS study underwent standardized magnetic resonance imaging, neurological examination, and neuropsychological testing at years 4 and 5. Predictors of cognitive impairment at year 5 were identified using multivariate analysis.ResultsOf 331 patients who completed the 3-year COGIMUS study, 265 participated in the 2-year extension study, 201 of whom (75.8%; sc IFN β-1a three times weekly: 44 µg, n = …

AdultMalemedicine.medical_specialty5 year follow upMultiple SclerosisAdolescentScienceInjections SubcutaneousBrain damageYoung AdultInterferonRecurrenceInternal medicinemedicineHumansIn patientYoung adultCognitive impairmentSex CharacteristicsMultidisciplinarymedicine.diagnostic_testbusiness.industryMultiple sclerosisQRMultiple Sclerosis Subcutaneous interferon β-1a cognitive impairmentMagnetic resonance imagingInterferon-betamedicine.diseaseTreatment OutcomeImmunologyMedicineFemaleSettore MED/26 - Neurologiamedicine.symptomSafetybusinessCognition DisordersInterferon beta-1amedicine.drugResearch ArticleFollow-Up Studies
researchProduct

When the amnestic mild cognitive impairment disappears: characterisation of the memory profile

2009

BACKGROUND/OBJECTIVES: Subjects affected by mild cognitive impairment (MCI) may improve during the observation period. This is the first study investigating qualitative features of memory deficits in subjects affected by reversible MCI [reversible cognitive impairment (RCI)]. METHODS: Baseline cognitive and memory performances of 18 subjects affected by amnestic MCI who had normalized cognitive performances at follow-ups were compared with those of 76 amnestic MCI subjects who still showed impaired cognitive performances at the 24-month follow-up (MCI) and with those of a group of 87 matched control subjects (normal controls). RESULTS: Compared with normal controls the memory deficit in the…

MalememorianeuropsychologyAudiologyNeuropsychological TestsAlzheimer diseaseMemoryMild cognitive impairmentNeuropsychologyPreclinical dementiadeterioramento cognitivo lieveLong-term memoryCognitive disorderNeuropsychologypreclinical dementiaCognitionGeneral MedicinePsychiatry and Mental healthNeuropsychology and Physiological PsychologyMemory Short-TermDisease ProgressionFemaleSettore MED/26 - Neurologiamedicine.symptomAlzheimer's diseasePsychologymedicine.medical_specialtyCognitive NeuroscienceAmnesiaHumans; Alzheimer Disease; Disease Progression; Aged; Mental Recall; Cognition Disorders; Memory; Memory Short-Term; Recognition (Psychology); Psychomotor Performance; Follow-Up Studies; Neuropsychological Tests; Amnesia; Female; MaleRecognition (Psychology)M-PSI/02 - PSICOBIOLOGIA E PSICOLOGIA FISIOLOGICAbehavioral disciplines and activitiesmild cognitive impairmentAlzheimer DiseaseMemorymental disordersNeuropsychologiamedicineHumansMemory disorderAgedMED/26 - NEUROLOGIARecognition Psychologymedicine.diseaseMCInervous system diseasesShort-TermMental Recallmild cognitive impairment; neuropsychology; memory; preclinical dementia; Alzheimer diseaseAmnesiaMED/09 - MEDICINA INTERNACognition Disordershuman activitiesNeurosciencePsychomotor PerformanceFollow-Up Studies
researchProduct

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results…

2009

Background Cognitive impairment is a common symptom of multiple sclerosis (MS), but the association between cognitive impairment and magnetic resonance imaging (MRI) disease measures in patients with relapsing–remitting (RR) MS is unclear. Objectives To study the prevalence of cognitive impairment and its relation with MRI disease measures in mildly disabled patients with RRMS. Methods Patients aged 18–50 years with RRMS (McDonald criteria) and an Expanded Disability Status Scale (EDSS) score ≤4.0, who were enrolled in the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study, underwent baseline standardized MRI complete neurological examination and neuropsychological testing. Results…

MalePediatricsIntelligenceRelapsing-RemittingNeuropsychological TestsSeverity of Illness IndexDisability EvaluationCognitionRisk FactorsOdds RatioPrevalenceNeuropsychological assessmentProspective StudiesNeurologic Examinationmedicine.diagnostic_testCognitive impairmet. Cognitive function. Multiple Sclerosis. Neuropsychological assessment.Cognitive disorderNeuropsychologyAge FactorsMiddle AgedMagnetic Resonance ImagingCognitive testTreatment OutcomeNeurologyItalyFemaleSettore MED/26 - NeurologiaPsychologyAdultmedicine.medical_specialtyMultiple SclerosisAdolescentNeurological examinationRisk AssessmentYoung AdultMultiple Sclerosis Relapsing-RemittingPredictive Value of TestsMagnetic Resonance Imaging; Young Adult; Age Factors; Odds Ratio; Immunologic Factors; Humans; Multiple Sclerosis Relapsing-Remitting; Cognition; Italy; Risk Assessment; Adult; Treatment Outcome; Adolescent; Neuropsychological Tests; Male; Severity of Illness Index; Neurologic Examination; Interferon-beta; Predictive Value of Tests; Cognition Disorders; Cross-Sectional Studies; Intelligence; Prospective Studies; Risk Factors; Disability Evaluation; Middle Aged; Female; PrevalencemedicineHumansImmunologic FactorsExpanded Disability Status ScaleMultiple sclerosisMcDonald criteriaInterferon-betamedicine.diseaseCross-Sectional StudiesPhysical therapyNeurology (clinical)Cognition Disorders
researchProduct